Should I prescribe low‑dose aspirin (81 mg) for a patient who is traveling by air and has elevated hemoglobin and hematocrit?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should You Prescribe Baby Aspirin for Air Travel with Elevated Hemoglobin/Hematocrit?

No, do not routinely prescribe aspirin for air travel based solely on elevated hemoglobin and hematocrit—aspirin is only recommended for travelers at substantially increased VTE risk when LMWH or compression stockings are not feasible.

Risk Stratification is Critical

The 2018 American Society of Hematology guidelines provide clear algorithmic guidance for air travelers 1:

Low-Risk Travelers (No Additional Risk Factors)

  • Do not prescribe aspirin, LMWH, or compression stockings for VTE prophylaxis in long-distance (>4 hours) travelers without other risk factors 1
  • Elevated hemoglobin/hematocrit alone does not constitute "substantially increased VTE risk" as defined by the guidelines
  • The absolute risk of symptomatic DVT with air travel is only ~0.05% (1 per 4,600 flights) 1

High-Risk Travelers (≥2 Risk Factors Required)

Aspirin becomes an option only when patients have substantially increased VTE risk, defined as 1:

  • Recent surgery
  • History of VTE
  • Postpartum status
  • Active malignancy
  • ≥2 risk factors combined (including hormone replacement therapy, obesity, pregnancy)

Even in high-risk patients, aspirin is third-line: Graduated compression stockings or prophylactic LMWH are preferred 1. Aspirin is suggested only when LMWH or compression stockings are "not feasible" (resource-constrained settings or patient aversion) 1.

The Polycythemia Vera Exception

If your patient has polycythemia vera (not just isolated elevated hemoglobin/hematocrit), the recommendation changes dramatically. Low-dose aspirin (81 mg daily) should be prescribed to all polycythemia vera patients without contraindications, as it reduces both arterial and venous thrombosis with acceptable bleeding risk 2. However, this is for the underlying myeloproliferative disorder itself, not specifically for air travel prophylaxis.

Practical Algorithm

Step 1: Determine if elevated hemoglobin/hematocrit represents:

  • Primary polycythemia vera → Prescribe 81 mg aspirin daily regardless of travel 2
  • Secondary polycythemia or isolated lab abnormality → Proceed to Step 2

Step 2: Count additional VTE risk factors:

  • 0-1 risk factors → No prophylaxis for air travel 1
  • ≥2 risk factors → Offer compression stockings or LMWH first 1
  • ≥2 risk factors + cannot use stockings/LMWH → Consider aspirin 81 mg 1

Important Caveats

Bleeding risk considerations: Aspirin increases major bleeding risk (OR 2.2) 3, and recent evidence shows it causes hemoglobin decline over time (additional -0.6 g/L per 5 years) and increased anemia incidence (HR 1.20) 4. In elderly patients with already elevated hemoglobin, this may seem paradoxically beneficial, but the bleeding risk remains real.

Evidence quality: All ASH recommendations for travel-related VTE prophylaxis carry "very low certainty in the evidence" 1, meaning these are conditional suggestions based on limited data. The guidelines explicitly note uncertainty about whether patients with elevated hemoglobin/hematocrit have multiplicatively increased risk with air travel.

Dosing if prescribed: If aspirin is indicated, use 81 mg daily 5. Higher doses (325 mg) provide no additional cardiovascular benefit but increase gastrointestinal bleeding 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.